Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
August 6, 2020
Earnings Call Speaker Segments
Jennifer Ruddock
executiveThanks, Crystal. Hi everybody, and thanks for being with us this afternoon. Joining us today are Howard Robin, our President and CEO; Gil Labrucherie, our COO and CFO; Dr. Jonathan Zalevsky, our Chief of Research and Development; and Dr. Wei Lin, our Head of Development. On this call, we're going to make forward-looking statements about our business, including clinical trial enrollment and clinical trial results, the timing of and plans for upcoming clinical trials, the timing of and plans for upcoming clinical data presentations, and how much therapeutic potential our drug candidates hold; we'll also discuss outcomes and plans for health authority regulatory actions and decisions, estimates and predictions concerning how the COVID-19 pandemic affects our business and clinical trials, financial guidance, and certain other statements about the future of our business. Since these forward-looking statements concern the future, they carry inherent uncertainties and risks that are hard to predict, and many of them lie outside our control. Important risks and uncertainties appear in our Form 10-Q filed on May 8, 2020, which you can find at sec.gov. We're not obligated to update any of these forward-looking statements, whether because of new information, future developments, or anything else. A webcast of this call will be accessible on the IR page at Nektar's website, nektar.com. Before I turn things over to Howard, I want to mention one small housekeeping item. Because shelter-in-place restrictions continue in San Francisco, all of us are, once again, dialing in from separate locations; so to keep the call flowing smoothly, I'll be moderating the Q&A session for our team, which lets us steer clear of technical problems during that portion; we thank you for your patience while we work to make sure there are no technology disruptions for our listeners. Having said that, I'll pass the call to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveJennifer, thank you — and thanks to all of you for being with us on today's call. To kick things off, I want to walk through how we've effectively guided this business, along with what we achieved in the second quarter and so far this year. Everyone of us based in the numerous regions where we run operations and conduct clinical trials still confronts a complicated landscape brought about by COVID-19. Making our way through this shifting set of circumstances while keeping disruption to the business to a minimum has been our primary objective. Thanks to those efforts, we've — progress has kept coming when it comes to moving our registrational and earlier-stage clinical trials forward, and our research and manufacturing work has carried on too, despite what the COVID-19 pandemic has thrown at us; we closed out the second quarter exceptionally strong. A substantial pipeline has been assembled across oncology and immunology, with numerous registrational and earlier-stage clinical trials now running, and we finished the second quarter financially sound, holding $1.2 billion in cash and investments, with zero debt on the balance sheet. Over this period, we've adjusted how we do things so that we can safeguard employee health while keeping critical operations going at our sites, including laboratory-based research and manufacturing work, which our business depends on; in addition, we've put in relentless effort alongside our trial investigators and their teams to make sure they can keep delivering outstanding care and uninterrupted access to study treatment for patients battling cancer within our clinical trials. Last, we've worked hard to keep the execution of our clinical trials from being significantly affected by the changing circumstances, and to ensure the integrity and quality of data gathered from those studies is preserved and monitored as it should be. Wei is going to cover these points more thoroughly afterward on this call. With all of that as context, we advanced considerably on many fronts in the second quarter, among them continuing to enroll new patients into our clinical studies so our enrollment time lines can be met, while simultaneously offering solid oversight of trial conduct and support to our trial sites; we've collaborated closely with our pharmaceutical partners here as well, and I'll share further updates shortly; manufacturing has seen no supply interruptions, and our ongoing preparations for commercial supply of bempeg stay on track. A lot of you keep asking how we view the present clinical trial time lines, or whether any of our clinical studies have been affected by COVID, and today I'll go through where the time lines for our studies currently stand. Throughout a fluid and uncertain period, we have monitored time lines for every one of our studies extremely closely, and we will need to keep evaluating those time lines, along with any effect on patients enrolled in our clinical studies, all through this year. During this quarter, we maintained an intense emphasis on supervising and moving forward the 5 registrational trials involving bempeg plus nivo under the BMS-Nektar joint development program. Those consist of the study in first-line metastatic melanoma, the trial in first-line bladder cancer, the first-line renal cell carcinoma study, the muscle-invasive bladder cancer trial, and the adjuvant melanoma study. Beyond those registrational trials, we are likewise making solid headway with the PROPEL study of bempeg plus pembro, the NKTR-262 REVEAL study alongside bempeg, and lastly the NKTR-255 trial in hematological malignancies. To begin, let's turn to adjuvant melanoma. We are especially happy to share today that Nektar hit our objective of launching this Phase III trial of bempeg plus nivolumab, which is designed to enroll 950 patients. Our team managed to get this trial underway in early Q3, which came in ahead of the schedule we had originally set, with the initial patients in the study beginning screening only last week. This trial matters a great deal, as it extends the breakthrough designation we obtained with a doublet in metastatic melanoma; during Q2, we recorded a fresh $25 million milestone payment from BMS tied to the study start. I take real pride in our team and in how well we have progressed and executed here; as for the first-line metastatic melanoma study, which our partner BMS is running, beginning in July, BMS has managed to successfully restart enrollment activities for this trial across many countries. They likewise intend to add more sites to the study so they can compensate for the time lost because of the COVID pause. During the recent analyst event, BMS signaled that initial data from the melanoma study should be anticipated in Q4 of '21 or Q1 of '22, and that lines up fairly well with how we sized up the situation, which we shared last quarter, that we anticipated enrollment delays tied to COVID might push time lines out by as much as 6 months. Although all of us are disappointed by the time line delay caused by COVID-19, we are quite pleased to observe BMS actively resuming enrollment activities that had been halted because of the pandemic, and that they are striving to hit these revised time lines for such an important study. A number of you have heard the BMS analyst call this morning, and — during which they emphasized bempeg as a key next generational late-stage medicine in IO that has demonstrated proof-of-concept within their development pipeline. Turning to the first-line bladder cancer study, we anticipate staying on track to hit our enrollment target late this summer. As a reminder, the primary endpoints for the study are ORR and duration of response by independent review among patients with a CPS score under 10. Depending on how long we track patients for duration of response, we are projecting a time line for reaching top line results for this study in the second half of '21, in line with the guidance we gave previously. Regarding our trial in first-line renal cell carcinoma, enrollment is still progressing as we projected, so we continue to anticipate that the initial interim analysis for the primary overall survival endpoint could occur during Q1 of 2022, which aligns with what we previously told you. Turning to the first-line muscle-invasive bladder cancer trial, that one is being conducted by BMS, and it is currently enrolling roughly 540 subjects who will get bempeg plus nivo, or nivo alone, over a 12-month treatment window after their surgery. Recruitment is ongoing, and additional sites are coming on board as the year goes on. Because this particular study has a longer timeline, our expectation is that the earliest data readouts will arrive in 2024; when it comes to the earlier-stage trials of bempeg within the BMS and Nektar development program, BMS intends to launch one more study involving bempeg plus nivo alongside a TKI for first-line renal cell carcinoma patients. That trial is built upon the registrational RCC study we are conducting, which compares the doublet of bempeg plus nivo against a TKI.
Howard Robin
executiveRegarding the initial treatment setting for non-small cell lung cancer, Nektar—as everyone knows—ran the PROPEL study evaluating bempeg alongside pembro on its own, outside of the BMS development effort, with the goal of seeking a registrational pathway in that disease by pairing bempeg with pembrolizumab, which is presently the favored standard of care. Establishing a path for development and regulatory approval of bempeg combined with nivo is rather challenging, given that nivolumab lacks any single-agent indication for first-line non-small cell lung cancer. BMS recently told us they won't launch the Phase II trial in first-line non-small cell lung cancer testing bempeg plus nivo that our amended agreement had described, so under that agreement, Nektar's exclusivity obligations tied to pushing forward registrational or other non-small cell lung cancer trials with BMS are now gone. Since pembrolizumab is solidly the preferred standard of care, we can now act swiftly on our plan for a registrational trial in first-line non-small cell lung cancer using pembro, contingent on positive results from PROPEL. Right now, patients are being enrolled in PROPEL, and that matches the timeline goals we set. That said, we mentioned last quarter that COVID-19 had delayed the study's launch. For PROPEL, we were able to get several additional sites up and running in Europe during the second quarter, and those locations are currently signing up patients. We expect to remain on schedule to deliver initial safety findings plus preliminary ORR results for 10 to 20 patients — each having at least 2 on-treatment scans — drawn from both the dose escalation portion and the non-small cell lung cancer cohorts of the trial by the close of this year or in the first quarter of '21. Similarly, our Phase I/II REVEAL trial evaluating NKTR-262 is proceeding according to plan. Currently, we're in the dose-expansion portion of the study. In this part, we're looking at giving the recommended Phase II dose of NKTR-262 at the same time as bempeg, either with or without nivolumab, in a group of up to 24 patients who have relapsed or refractory melanoma. During our last quarterly update, we mentioned that when NKTR-262 and bempeg were administered one after the other, we observed elevated TLR activation within the tumor microenvironment, and we were able to establish the safety profile for NKTR-262. We've submitted these findings for a presentation at the SITC Congress in November, and they support our decision to advance this program into the relapsed and refractory melanoma population after those patients have received IO therapies. Turning to NKTR-255, which is our IL-15 agonist and the cytokine treatment that follows in the clinic, enrollment is currently underway for the first-in-human trial in patients who have blood cancers, and that study began late last year. Our target is to complete the monotherapy dose escalation phase before this year ends. Of course, reaching that target depends on the number of dose cohorts we need to enroll prior to identifying a maximum tolerated dose. As a reminder, during dose escalation this study evaluates NKTR-255 as a monotherapy, and afterward we will broaden it into several arms. In these trial groups, NKTR-255 will be evaluated both as a standalone treatment at the recommended Phase II dose and in combination — paired with daratumumab for multiple myeloma patients, and with rituximab for those with non-Hodgkin's lymphoma. Starting from the very first dose level examined, we have observed target engagement along the IL-15 pathway, and we are eager to share these early findings at the SITC Congress taking place this year. As interest continues to rise in natural killer cell therapies, our strategy for NKTR-255 development spans a broad range of cancer types. In addition to the ongoing heme malignancy trials, we plan to begin studying NKTR-255 in solid tumor patients prior to the close of this year. JZ will provide further details on that trial in a moment. Now let's discuss Eli Lilly, our collaborator on NKTR-358, which is our Treg stimulatory program. At the EULAR Congress not long ago, we shared results from the Phase Ib trial of NKTR-358 involving individuals suffering from mild-to-moderate lupus. Those compelling findings paved the way for the Phase II trial, which Lilly is likewise conducting among patients who have moderate-to-severe lupus. I'm delighted to share that Lilly started setting up clinical locations in late July, and this week they began screening participants for that trial. Later during this call, JZ will provide further details about this study. Beyond that, the Phase I multiple dose trial in psoriasis and atopic dermatitis that Lilly is running has resumed enrolling patients following a 3-month halt prompted by the COVID-19 situation. To wrap up, we're planning to share more findings about NKTR-358 from the Phase Ib trial at the 2020 American College of Rheumatology Congress — that's ACR — happening in early November. Everyone here is eager to bring you that fresh NKTR-358 information. And lastly, Lilly intends to kick off an additional Phase II trial in a different autoimmune condition during this year's second half; we're quite happy about Lilly's ongoing dedication to NKTR-358 and their extensive development strategy, which speaks to how this genuinely innovative mechanism could become a key player in treating many kinds of autoimmune diseases. Prior to passing things over to Wei, I want to bring up some extra data we intend to present for bempeg during this year. To begin, regarding the melanoma cohort from PIVOT-02, most of you are aware that in the prior year we secured an FDA breakthrough therapy designation for the combination of bempeg plus nivo in metastatic melanoma patients, which was based on favorable results from the PIVOT-02 trial, among them a RECIST complete response rate reaching 34%, and 42% of those patients saw their RECIST target lesions disappear entirely. As mentioned during our previous call, when patients in this cohort reached the 21-month median follow-up mark, median PFS had still not been reached. We keep observing that these patients are responding more strongly over time, and we're really looking forward to submitting fresh results from the melanoma cohort using a data cutoff that's even later and nearer to the SITC 2020 meeting happening this year. We also intend to share some initial landmark survival findings. As we've mentioned previously, we're quite enthusiastic about what this doublet combination could do for people with melanoma. So at this year's SITC Congress, we're planning to show results from 3 Nektar programs. We've got fresh data to share from the metastatic melanoma group receiving Mé as their initial treatment, which I touched on earlier. We also have outcomes for the earliest participants enrolled in the NKTR-255 study, which focuses on blood cancers, plus findings from the dose escalation phase of the NKTR-262 trial. Having said that, I'll now pass things along to Wei, who will walk everyone through the bempeg development program in more depth.
Wei Lin
executiveThank you, Howard. Like Howard mentioned, we're still doing everything we can to keep our clinical studies on schedule in light of the COVID pandemic; beyond the strict methods our study teams use to run our clinical trials, our monitors and data collection systems are also logging any COVID-related protocol deviations or shifts in study conduct that we might later need to submit to the FDA. As you're aware, the FDA put out guidance on conducting clinical trials during the pandemic, and we're carefully tracking FDA guidance as we monitor any COVID impact on patients enrolled in our study. Patient compliance has looked very strong, especially when it comes to their visits to study sites for study treatments and for scheduled scans. We remain incredibly impressed by how deeply engaged our investigators and their staff are and by the remarkable care they're giving their patients throughout this extremely difficult period for everyone. In response to some questions we're getting, we've received just a handful of reports of patients in our studies with suspected or confirmed COVID infection. As of today, across the more than 200 investigator sites worldwide where Nektar is running clinical studies, we have a small number of reports of patients who were diagnosed with COVID or who missed study treatment or study scans because of COVID. We're diligently gathering all information tied to these cases and any other study impact potentially linked to COVID, and we're following FDA guidance so we can report any COVID-related protocol deviations to the FDA and support future registration. Before I turn the call over to JZ to talk about our work with NKTR-358 and NKTR-255, I want to address the ongoing questions we've gotten about switching the interim response rate endpoint from overall response rate, ORR, to complete response rate, CRR, in our first-line melanoma study. As you know, we were granted a breakthrough therapy designation for bempeg plus nivo based on the high complete response rate seen in this patient population. In the Phase III study, we have 3 endpoints, overall response rate, or ORR, progression-free survival, or PFS, and overall survival, OS. The first endpoint is an interim analysis in which a very small amount of alpha is spent comparing the ORR in the doublet arm of bempeg plus nivo against the ORR in the nivo monotherapy arm, and that analysis will be conducted in a specific number of patients with at least 6 months of follow-up; this endpoint opens the door to a possible early accelerated filing for the doublet so we could deliver an innovative treatment to patients sooner. The full approval filing in the U.S; and in Europe will rest on PFS and OS. Given our high complete response rate, many of you have asked whether we could swap the interim ORR endpoint to instead examine the complete response rate. Our partner BMS and we keep looking into that option, which includes reaching out to worldwide health regulators to talk about the best way to back this approval route. What matters most to both firms while this goes on is preserving the soundness of the Phase III study that is currently running, so the findings from it can be applied toward worldwide approval of bempeg plus nivo in first-line melanoma. This could take a while. Even so, we hold hope that we might be able to share an update on it prior to the close of this year. During this period, the trial still carries its initial 3 endpoints: ORR, PFS and OS. The trial's initial blueprint follows CheckMate 67, and the PFS readout is expected to happen roughly 6 to 7 months following the first interim look at ORR. That said, this expectation is shaped by how quickly patients enroll and how quickly PFS events arise in the trial. So the schedule might shift. For ORR as well as PFS, blinded independent radiology review will be used to assess the findings. That means this course of action will also influence when any data analysis can be finished. As we draw nearer to reaching these endpoints, we can sharpen our timeline and make it public. As I mentioned a moment ago, ORR serves as an accelerated approval endpoint, we devoted just a modest quantity of alpha to it, and PFS is the endpoint for full approval. With that, I'll pass the call to JZ so he can talk further about our NKTR-358 and NKTR-255 program. JZ?
Jonathan Zalevsky
executiveThank you, Wei. There are 2 programs I want to cover in a bit more depth. NKTR-358 and what we intend to do with the lupus trial is the first, while our IL-15 effort, NKTR-255, is the second. Starting with NKTR-358: as Howard mentioned, we shared initial results from the Phase Ib multiple-ascending dose trial, run in individuals suffering from mild-to-moderate lupus, at this year's European League Against Rheumatism, or EULAR, meeting held in early June. No other company has come forward with data from a multiple ascending dose trial of a novel Treg stimulating therapy in patients besides us. We're extremely happy that this encouraging data has resulted in our collaborator, Eli Lilly, launching a Phase II trial in lupus patients, with a second Phase II planned in a different autoimmune indication before the year is out. A number of autoimmune conditions, systemic lupus among them, involve lower Treg counts, diminished Treg activity and/or less IL-2 being produced. Such Treg deficiencies play a significant role in how these autoimmune illnesses develop. Through NKTR-358, we aim to tackle these Treg abnormalities and the disease itself, and to create an IL-2-like molecule capable of selectively stimulating Tregs far more effectively than IL-2 does. Findings from the Phase I trial shared at EULAR led to the conclusion that NKTR-358 was safe and well tolerated across multiple doses given to lupus patients; this backs up what our earlier single-dose work in healthy volunteers showed. On top of that, proving the safety profile looked alike whether given once or repeatedly mattered greatly for possible therapies targeting chronic disease. The data additionally revealed dose proportional PK along with prolonged exposure, with a half-life spanning 10 to 13 days, which readily supports dosing every 2 weeks in the Phase II trial. Crucially, NKTR-358 produced a pronounced, selective and dose-dependent increase in proliferating Tregs among lupus patients, and this held up across multiple-dose administrations. As Howard noted before, the Phase IIb trial is currently ongoing, with Lilly conducting it. Regarding the patient population, it mirrors other Phase IIb lupus trials when it comes to needing an SLE diagnosis via ACR classification criteria, positive autoantibodies typical of lupus, and active clinical disease activity despite standard of care treatment. For this trial, patients need a systemic lupus erythematosus disease activity index, or SLEDAI-2k, above 6 points when screened. Furthermore, patients need a measurable degree of clinical activity at baseline, encompassing secondary organ manifestations like arthritic joints or skin involvement. Patients got randomized into 1 of 3 NKTR-358 dosages given every 2 weeks, or placebo, across a treatment period lasting 6 months, or 24 weeks. The primary endpoint for the Phase II trial is the percent of patients reaching a reduction of at least 4 points on the SLEDAI-2k scale. Key secondary endpoints encompass the percent of patients attaining an SRI-4 response, a BILAG-based BICLA response, and the level of low disease as defined by the lupus low disease activity state, or LLDAS. Additionally, we're going to look at pharmacokinetics, pharmacodynamics, and immunogenicity in patients who receive treatment. At week 24, all primary and key secondary endpoints will be assessed, and we anticipate finishing this study in 18 to 24 months. Now, turning to NKTR-255. As Howard mentioned, the dose escalation portion of this Phase I/II trial in patients with heme malignancies is moving forward, and we intend to share initial data from the first patients in that dose escalation at the SITC Congress this November. This study is assessing the safety, pharmacokinetics, and pharmacodynamics of NKTR-255 in hematological malignancies, with the aim of identifying a Phase II dose for use both as a monotherapy and, in parallel, tested alongside antibodies that act through an ADCC mechanism, such as daratumumab and rituximab. Depending on the number of dose cohorts we go through, we intend to enroll as many as 40 patients with relapsed or refractory multiple myeloma and non-Hodgkin lymphoma in the dose escalation portion. We've also brought a robust biomarker program into this trial, which includes measuring how NKTR-255 affects multiple immune cell populations in both peripheral blood and lymphoid tissues. We're particularly focused on the expansion of NK cell numbers and analyzing NK cell subsets, along with their activation and function. As Howard said, our aim is to finish the dose escalation monotherapy portion of the Phase I trial by the end of this year, and we're enthusiastic about the early biomarker results we've seen in the first patients enrolled. So we're eager to share those with you in November. In addition, we're planning to launch a second Phase I/II study of NKTR-255 in solid tumors before this year ends. This trial will assess NKTR-255 in 2 solid tumor settings combined with cetuximab. The first setting is head and neck cancer, enrolling patients whose disease has progressed on platinum therapy and a checkpoint. The second setting is metastatic colorectal cancer, enrolling patients who've had 2 prior metastatic treatments. The overall study will enroll as many as 75 patients and will feature a dose escalation component for a combination regimen, then expand into dedicated cohorts in head and neck and colorectal cancer; and with that update, I'll hand the call over to Gil for a review of the financials.
Gil Labrucherie
executiveThanks, JZ, and good afternoon to all of you. During this call, I'll go over the financial guidance we've provided for 2020, and that guidance has not changed. Let me begin with the strength of our financial position: in the second quarter, we paid off $250 million of senior notes that were outstanding, so we finished the quarter holding $1.2 billion in cash and investments, with no debt at all on our balance sheet. Our plan is still to close out 2020 with more than $1 billion in cash and investments. Now to the guidance for the year. For 2020, our full year GAAP revenue guidance is still in the range of $140 million to $145 million. Within that figure is $50 million coming from BMS milestone payments, plus $90 million to $95 million from royalties, product sales and other revenue. In Q1, we recorded a $25 million milestone tied to the launch of the muscle-invasive bladder cancer study. And, as Howard noted, we got the adjuvant melanoma study going successfully, ahead of when we expected, and in Q2 we recognized a second $25 million milestone under the BMS collaboration, instead of in Q3, which is when we had projected it last quarter. That remaining $90 million to $95 million of GAAP revenue should still be recognized on a fairly ratable basis across the 4 quarters of this year. Our GAAP R&D expense guidance is unchanged as well, since progress in our clinical pipeline is largely staying on track. For 2020, we expect GAAP R&D expense to fall between $475 million and $500 million, and that figure includes roughly $70 million of noncash depreciation and stock compensation expense. G&A expense for 2020 is still expected to land between $105 million and $115 million, including approximately $45 million of noncash depreciation and stock compensation expense. We keep managing our operating expenses carefully, and we stay highly focused on carrying out our broad portfolio of research and development programs. And as I went through earlier, we intend to finish 2020 with no less than $1 billion in cash and investments. With that, I'll turn the call over to questions. Operator?<<operator_script>> Our first question comes from Peter Lawson of Barclays.
Peter Lawson
analystTurning to the initial clinical results we have for 262 and 255, is there a particular aspect worth concentrating on, and what ought we to anticipate? Also, is there anything to which we should direct our attention?
Jennifer Ruddock
executiveJZ, that question is one I would like you to take.
Jonathan Zalevsky
executiveAbsolutely, Peter, and thank you. So it's true that we're getting preliminary results from each of these programs, and in both cases those come from first-in-human trials. What we really focus on, then, is the purpose behind each study and how it was structured. These trials are set up to evaluate the general tolerability and safety profile of the agents, and additionally to evaluate pharmacokinetics as well as pharmacodynamics. As you're aware, we place a great deal of emphasis on the mechanism of action behind these drugs. That emphasis is genuinely woven into the way we conduct our drug development, particularly during the early phases. Both trials therefore incorporate strong biomarker components. In the case of NKTR-262 within REVEAL, we're examining important biomarkers tied to activation of TLR 7 and 8. Keep in mind that during the first cycle, we're able to measure those under monotherapy. Then we also measure them when combined with bempeg across subsequent cycles. Bear in mind that this trial follows a staggered structure, since it represented a first-in-human study of a novel-novel pairing. In that context, we'll be watching the type 1 interferon responses triggered by TLR activation very carefully. Meanwhile, the type 2 interferon response comes from bempeg. After that, we examine what happens when the 2 are combined and patients keep receiving treatment. With regard to 255, as you know, that cytokine differs from bempeg. It also triggers a separate group of immunological pathways. So, as I said earlier during my presentation, they are probing extremely deeply into specific immune-related tissue and blood-based cellular compartments. We're especially concentrating on natural killer cells. NK cells represent a strong target for engagement of the IL-15 pathway, and NKTR-255 engages that compartment quite effectively. Consequently, we don't merely examine total book numbers; we go as far as examining distinct subsets of NK cells. We even look at precursor and early maturing immune cells too. Beyond that, we'll investigate activation markers and take it further into broader markers of effector function. That describes the type of data we'll be concentrating on, and hopefully it gives you a sense of what sort of data you can look forward to seeing later this year.
Peter Lawson
analystAll right, and what's the potential patient count we might observe? Also, is it possible we'll see early clinical efficacy, or is that premature?
Jonathan Zalevsky
executiveYeah. Regarding the 255, that's going to be a subset, as we said, with that trial continuing, dose escalation. It'll therefore be an initial group of cohorts. And within REVEAL, we've got the full dose escalation progressing through determination of the recommended Phase II dose, which is currently under investigation in bigger cohorts. So we will absolutely show all data that exists. We said previously that we'd seen cases of responses in REVEAL, and that information was shared by us last year. So we'll keep adding to all of that; however, to your point, it's truly once we get into the bigger cohorts that trials begin enrolling patients at low — sufficiently large patient groups, correct, that we'll pinpoint efficacy.
Tyler Van Buren
analystNice work on everything so far. So, two things from me. My initial one concerns PROPEL, that study in first-line non-small cell lung cancer combining with pembro. We should be seeing preliminary results somewhere between the end of this year and the start of next, and you mentioned that overall response rate figures might come from 10 or 20 patients who've had more than 2 scans. Could you walk us through what pembro given alone would typically demonstrate at that stage? And with that in mind, what level of overall response rate for the combination would give you real confidence to keep pushing it forward? My second one has to do with the pathway you're pursuing, possibly in first-line melanoma, to shift that interim readout away from overall response rate toward a CR rate interim look — which makes sense, obviously, since the delta is wider there. But I'd like to hear what case you'll present to the FDA and the regulatory agencies in order to secure that adjustment.
Jennifer Ruddock
executiveThanks, Tyler. Wei, could you take folks back through the PROPEL design and the various cohorts we're evaluating in non-small cell lung cancer, and address Tyler's first question?
Wei Lin
executiveAll right, of course, definitely. Thank you for asking that. For sure, I'd say that even given the progress made lately, non-small cell lung cancer continues to represent a significant area where patients still need better options. Let me explain — we're starting from the existing standard of care, which is pembro given by itself. As you're aware, this cancer is actually divided into 3 distinct groups according to PD-L1 status. There's the group at 50% and above for PD-L1 expression, the group from 1% to 49%, and the group below 1%. And each has its own benchmarks. For those at 50% and above and those between 1% and 49%, what a single agent achieves is definitely not the same, and that differs as well from the under 1% group, where pem mono doesn't actually have approval. Since we have these response data available for pembro monotherapy, we're able to assess the added benefit or possible synergy that bempeg combined with pembrolizumab might deliver; that's the approach we'll take to truly assess the data. So regarding how our PROPEL study is designed, to begin with, the study has 2 parts. There's an optimization cohort along with an expansion cohort in non-small cell lung cancer. And to directly get at what you asked, I'll concentrate on the expansion cohort in non-small cell lung cancer; within that, we've actually split the patient groups so we enroll separately those at 50% and above, those from 1% to 49%, and those below 1%, which aligns with how treatment is currently segmented between pembro monotherapy or pembro plus chemo across these segments, and also reflects awareness of the differing benchmarks. That's really how we intend to examine the data. So roughly 20 patients will be enrolled in each of these subgroups, adding up to approximately 60 patients overall. Then, drawing on the response we see among those at 50% and above, those from 1% to 49%, and those below 1%, and comparing against pembro monotherapy, that's the basis on which we'll determine whether additivity or synergy might potentially be seen from combining pembrolizumab and bempeg, and our upcoming registration trial in first-line non-small cell lung cancer would be based entirely on what we observe within each of these subgroups and on which population would be ideally enrolled into that future registration study; so yes — that covers the — our approach to examining the data when it comes to reaching a registration decision in non-small cell lung cancer. Jennifer, should I continue and likely address the melanoma...
Jennifer Ruddock
executiveSure. Could you give us a bit of insight into your approach to the CR endpoint and the kinds of things you're examining in that area?
Wei Lin
executiveOf course, certainly. In oncology, ORR has traditionally served as a kind of yardstick for evaluating a drug's early activity. That said, these response rate endpoints strike me as somewhat arbitrary, and how much weight they carry depends on their association with progression-free survival and, in the end, overall survival. What truly supported our evaluation — and indeed the case we are presenting to the FDA and to health authorities outside the U.S., including the EU and elsewhere — rests on the Venn analysis that the FDA shared around ASCO 2019. As a reminder, at that point the FDA had assembled all first-line metastatic melanoma patient data from every registration trial, no matter what kind of agent was involved — TKIs, BRAF inhibitors, or immuno-oncology therapies such as PD-1, PD-L1, or even CTLA-4. Drawing on all those first-line data in their database, they ran a meta-analysis and examined how different response rate endpoints correlate with progression-free survival and overall survival. What their analysis of close to 5,000 patients actually showed is that even past overall response rate, ORR, lies depth of response — the deeper that response, the more strongly it correlates with PFS and overall survival. So the link to long-term survival is greater for a 50% depth of response than for 25%, and greater still among patients reaching 75% tumor shrinkage versus 25%. And the best outcomes — those going to the patients achieving the most — belong to those with 100% shrinkage of their tumor. So that is genuinely the basis on which we propose shifting from ORR to CRR, given this stronger correlation with deeper response. The greatest response, or maximum depth of response, is of course a complete response. That is precisely what our data have shown — again from PIVOT-02, for the combination of bempeg plus nivolumab — where we reached a 34% response rate with only one year of follow-up, and we now have more than 21 months of follow-up. And that figure, 34%, exceeds what nivo or even nivo-ipi, the best standard of care currently available, had attained after 5 years of follow-up; they showed only a 21% complete response rate at 5 years of follow-up. And this is a figure that kept evolving and deepening over time, which is very typical of immunotherapy. So it is certainly our aspiration and hope that with longer follow-up, that complete response rate will grow both within the PIVOT-02 cohort and, in particular, in the registration study being run by our partner, BMS. So I think this is really — I think the case we are putting to the health organization is that, per the FDA analysis, depth of response correlates most strongly with long-term survival, and of all the depth of response measures, complete response correlates most strongly of all. And if a single surrogate endpoint based on response rate were to be used, it ought to be a CRR endpoint. And given that solid connection, that ought to be applied when doing the initial evaluation for accelerated approval. So that's the case we're putting forward.
Hiroshi Shibutani
analystIf I could, I have a pair of questions. Regarding 358, could you remind us — and I'm sorry if this was covered already — about psoriasis and AD. Are we going to get data on that, and if we are, at what point? From what I understand, Lilly has started a Phase II trial in one of those indications at some point this year, or at least that's what's intended. And once that data comes out, is it simply going to be PK-PD like we saw with lupus? Or might we also get a look at some early efficacy endpoints?
Jennifer Ruddock
executiveThanks, Chris. JZ, would you handle the 358 question.
Jonathan Zalevsky
executiveRight, Chris. To make that clear, Lilly has 2 Phase Ib trials underway — one focused on psoriasis, the other on atopic dermatitis. During the call, we also noted that when the COVID pandemic emerged, Lilly's initial move was to halt those trials, which was entirely logical. They're non-oncology trials, after all — the chronic, nonlife threatening conditions. Yet, as was mentioned earlier during this call, those trials have since resumed and are now recruiting patients. Consequently, we don't anticipate presenting data from them within this year. Enrollment is still ongoing for those trials, though it's plausible that toward the close of next year, seeing some data from them would be plausible; and regarding the type of data you might see, since these are Phase Ib trials, they certainly include a substantial pharmacokinetics element along with a pharmacodynamic one. Something else worth noting: numerous biomarkers have been incorporated, particularly — as you're aware, Chris, given how familiar you are with many skin studies — skin biopsies and punch biopsies are extremely, extremely feasible. So an evaluation will also take place of what's occurring locally within the skin, for instance, involving the various keratinocytes, things happening inside disease lesions, and especially a search for Treg infiltration, which could be quite disease beneficial. I hope that addresses your question.
Hiroshi Shibutani
analystRight, so given those 2 indications, how is Lilly going to decide which one gets launched first as a Phase 2 trial? And will there be any visibility into that choice at some point during 2020?
Jonathan Zalevsky
executiveCorrect. So a few years back, when we signed that deal with Lilly, it covered 4 Phase II studies; and Lilly strongly prefers the approach of keeping the indications under wraps for as long as possible, which helps them preserve a competitive edge and other benefits; that's why the lupus study has been made public, since it just got underway. Like we said, a second Phase II study is set to start later this year in another autoimmune indication — not lupus, a different one. And once we're nearer to that study kicking off, my expectation is that Lilly will reveal which indication it is; and after that, 2 additional indications are on the way — those too will be disclosed at a later point. And we anticipate both of those studies getting started next year.
Hiroshi Shibutani
analystExcellent. And for my brief second follow-up, these recent conference calls have often turned into those special surprise-reveal times in the Q&A, when you provide us with some kind of bempeg PIVOT-02 melanoma update. Did that slip past me? Is there anything at all you can tell us?
Jennifer Ruddock
executiveThat's something we're holding back for SITC, Chris.
Alexandre Bouilloux
analystThis is Alex sitting in for Difei. I had a question regarding the bladder cancer setting. I was wondering whether you might share your views on how you see the market opportunity there for bempeg, and where you believe the biggest unmet need lies, given how the competitive dynamics and the competitive landscape there are evolving?
Jennifer Ruddock
executiveSo Wei, would you like to take that question?
Wei Lin
executiveAbsolutely, glad to do that. So, looking back across the past 12 months, the picture for first-line metastatic bladder cancer keeps shifting, and we're starting to get a clearer view. Given how well avelumab has performed in that setting, maintenance treatment has now made its way into first-line bladder cancer; and after pembro failed in its registration trial alongside chemotherapy, combining it with chemo appears unlikely to become the go-to, dominant standard of care in first line. So the field stays fairly split, in that you still have disease entities classified as cisplatin-eligible and cisplatin-ineligible. And I'd say the way we treat these patients hasn't changed all that much — for those who can't get cisplatin, we're still dividing them into IO groups based on whether their PD-L1 status is positive or negative, right? What's become more evident, I'd argue, is that combining IO with chemo isn't going to end up being the go-to approach, the way it has in something like non-small cell lung cancer or head and neck cancer. That space remains pretty wide open for new agents that can deliver meaningful gains for patients undergoing that treatment. So with all that as background, among the promising options now being developed are not just our own bempeg plus nivolumab combo, but also PADCEV, which comes from Seattle Genetics, paired with pembrolizumab. And each regimen comes with its own advantages and drawbacks. In my view, ours is an immunotherapy-only treatment approach, and it keeps chemo available for use in later lines. The PADCEV plus pembro pairing, on the other hand, genuinely mixes in an ADC—which works as a rather clever chemotherapy foundation. So while early-stage results suggest the efficacy appears greater, the tolerability side is likely less favorable than what bempeg plus nivo offers. Because of that, I'd say how this plays out hinges on the early-phase information, some of which we've already shared with the public, along with what Seattle Genetics and Merck come forward with. The real clinical benefit from the registration trial is still something we have to wait and see about. When we talk about the greatest unmet need, that's still the cisplatin-ineligible group, in our view. So on one side, these patients can't get the strongest, most effective chemo agents used against bladder cancer; on the other side, those who are PD-L1-negative have no access to IO therapy as a first-line option. That's the reason I'd argue our approach to development continues to make a lot of sense right now, despite everything shifting in the treatment landscape. Our view is unchanged that the greatest unmet need sits with those patients who can receive cisplatin and who test negative for PD-L1 — that particular subgroup. Likewise, I'd say our registration plan keeps us in a position to become a possible new therapy choice, provided we can get PIVOT-10 across the finish line successfully. We're certainly optimistic about being able to reproduce what we saw in PIVOT-02, and we still stand behind those findings — they could translate into real, meaningful benefit for patients. And I think how this gets used in this disease area is really going to come down, in the end, to both how safe and how effective our combination is, along with the pembro plus PADCEV combination. And I think the safety side will likely be one more important element. My view is that it's quite possible for the two of them to each find a route to approval, and ultimately how that plays out will depend on each patient's particular circumstances — what they require, plus how sick someone with bladder cancer happens to be. Many of these individuals have already had their bladder taken out, and they also live with additional illnesses, which could leave them unable to tolerate an especially harsh chemotherapy course or alternatives whose side effects resemble those of chemo.
Alexandre Bouilloux
analystAlright. Then, regarding PIVOT-02, is there any possibility you intend to share a PIVOT-02 update in bladder cancer ahead of the Phase III results?
Wei Lin
executiveYeah. What we've released publicly so far, at public congresses and during earnings calls, has been fairly mature. As for an upcoming update, our plan is to gather our PIVOT-02 findings, bladder cancer data included, into a follow-up publication, where we can, in a more definitive way — with more granularity, tease apart every nuance within the data and deliver a far more rigorous dataset through a publication than what a 5- to 10-minute congress presentation could ever allow.
Gobind Singh
analystGobind here, filling in for George. Only 2 things I want to ask about. First regarding 358, second about the bempeg program. On 358, as we look toward the data that's coming, I think it's the mild-to-moderate data, and JZ said the lupus disease activity index for the trial ahead will be taken above — or for this particular one, it was likely under 6%. So I'm attempting to work out whether we'll get biomarker data, whether there will be some — I'm simply not certain activity will appear and be shown. What ought we to view as a meaningful change? I completely recognize this wasn't a trial designed for F50, with the short treatment duration and everything like that. Then my second question, on the bempeg side: for the bempeg Keytruda program, could you remind us once more how bempeg managed to go higher? My understanding is that you're dose escalating it, really above what was done with OPDIVO, and with that larger dose, if you moved into other tumor indications, would you also be using this higher dose?
Jennifer Ruddock
executiveThanks, Gobind. I'll have JZ handle the first question about 358 and the ACR data we intend to present, then I'll ask Wei to take the second one on — returning to the PROPEL design and its dose escalation component. Thanks. JZ?
Jonathan Zalevsky
executiveAbsolutely, and thank you, Jennifer. Gobind, those are really thoughtful questions. You're completely correct. In study 358, the MAD portion involved patients whose lupus was mild to moderate. That means baseline disease severity varied quite a bit, and in certain instances it was extremely mild, since these individuals are taking steroids and their condition may be well controlled — a sharp contrast with the Phase IIb, where every participant will enter with a SLEDAI score of no less than 6. As a result, those individuals will be considerably further along in their disease, and each one will show clinical signs of illness, which does not hold true for the Phase Ib MAD. So the populations aren't the same. Beyond that, naturally, how long people are treated differs substantially. In the Phase Ib, treatment lasted 6 weeks, while in the Phase IIb it will run for 6 months. With all those meaningful distinctions in mind, what might you watch for? When we share further results from that trial, the first thing is that we'll be showing the same sort of extra collection of information that we showed for the single-ascending dose trial in healthy volunteers. We'll have considerably more biomarker findings. There will be substantially more FOXP3 and other Treg-related information, plus the possibility of some genetic gene expression results too. That's what we shared at ACR last year from the SAD data, so we'll be presenting those same supplementary biomarkers. On top of that, there's 1 more group of features: we actually do have assessments of disease activity — everything we captured, and we captured a variety of different endpoints, for example the SLEDAI scale, the classi scale, and others. So in a study like this, conducted early in this early context, what genuinely gets me enthusiastic is whether I observe changes that depend on dose. You wouldn't anticipate that over such a brief period of treatment there'd be a particularly dramatic effect on how the disease progresses. But should I detect dose-dependent shifts in a marker that can be measured clinically, that would truly excite me, and it would definitely be the sort of information that would give you real confidence to advance into the Phase IIb stage. So our goal will be — we'll be collaborating with Lilly, and we intend to present lots of additional aspects of that trial. So keep watching for it; that's also on the way in November, Gobind. And at this point, what I'll do is hand things over to you, Wei, to discuss the dose escalation and optimization part of the bempeg plus pembro program.
Wei Lin
executiveAppreciate it, JZ. That's a genuinely excellent question — why do we continue dose optimization while the molecule is headed for registration? Let me start by reminding everyone that the 6-microgram per kilogram dose paired with nivolumab in registration across a number of our programs remains a highly efficacious dose. That dose is the one for which we received breakthrough therapy designation from the FDA. It is highly active. It is truly a strong dose, and it delivers an outstanding safety profile — regarding immune-related AEs, we saw the same IMAE rate as with nivolumab given alone. That said, when you consider the whole oncology space and the range of tumor types, you can roughly sort them into a few categories based on how they respond to PD-L1 therapy. There are diseases such as melanoma and RCC where no PD-L1 biomarker is required; pembro alone and nivo alone perform extremely well in melanoma because of PD-L1 expression. In RCC, with a combination, a biomarker isn't needed whatsoever. Conversely, you have tumor types like non-small cell lung cancer, head and neck cancer, and particularly triple-negative breast cancer, where a biomarker is required. For both lung and head and neck, monotherapy only helps at a certain cut point or above for PD-L1 expression. Under that level, you truly need the boost that chemotherapy provides. And in triple-negative breast cancer, the data for both pembro and atezolo show that even with combination chemotherapy, PD-L1 negative patients gain no benefit from adding a checkpoint. So in certain tumor types, you clearly require additional inflammatory activity to actually shift the immune status of those tumors. Since bempeg is a pro-inflammatory cytokine, we believe it can supply that extra boost to immunotherapy. We certainly have clinical evidence suggesting this from PIVOT-02, where across several tumor types we demonstrated upregulation of PD-L1 and other inflammatory status markers in the tumor following just one dose of bempeg. In our bladder cancer cohort specifically, we had 10 patients, one of whom had on-treatment biopsies obtained; those patients received bempeg plus nivo. Then, before their second dose of bempeg-nivo and ahead of their 21-day follow-up, we took another biopsy, and that biopsy showed that a single dose of bempeg was able to convert 10 patients who had previously been PD-L1-negative — truly PD-L1 expression of 0 — into PD-1 positive; that's 7 out of 10. Which means, regarding the case at hand, we have plenty of drive to go after diseases that up to now have been unresponsive to checkpoint monotherapy by itself, or where even adding chemotherapy, as with TNBC, can't really convert them into an immunosensitive state. With bempeg added, I believe we're definitely in a position to test hypotheses in which bempeg supplies that immune inflammation needed to extend checkpoint efficacy across a wider set of tumor types — that's our main motivation. Is it feasible? Is it safe? We think it can be achieved, likely also owing to the abundance of data we've produced across all our ongoing programs. As we dose more and more patients and build better management guidelines to handle many of the adverse events tied to bempeg, particularly the cytokine-related toxicity, what we observe is that these are quite manageable, especially when guidelines are provided. Take one of them — hypotension, a dose-limiting toxicity of bempeg, can be handled very effectively simply through proactive hydration during cycle 1. Once we put that into practice, the hypotension rate fell dramatically. And we no longer see the high-grade event that we had typically encountered during very early dose escalation, back when these management guidelines, the hydration guidelines, were not yet in place. So we genuinely believe that under the current management guideline, bempeg's safety profile allows us to push the dose even higher while delivering a comparable safety profile on one hand, and on the other, generating even greater pro-inflammatory activity from our cytokine and perhaps, via combination with checkpoint, widening a checkpoint's activity to a broader patient population. Those are essentially the 2 main motivations. And I think there's some evidence we can truly pull this off. Then, if we manage to give a higher dose, we can certainly bring the combination into some of the tumor types I just mentioned, where PD-L1 expression is low for a large portion of patients and existing IO therapy shows no meaningful activity in those patients.
Gobind Singh
analystThat is genuinely useful. If I could squeeze in just one additional question, though. So does this suggest that with the new protocol, you have now determined what the fresh bempeg dose should be? And would you be willing to tell us what it is?
Wei Lin
executiveWell, it remains within dose isolation — the optimization cohort — and it is in fact active, Gobind. Then I believe we would share those results at an upcoming congress. As of now, no DLTs have turned up during our continuing dose escalation, though we would definitely be glad to present that data at a later congress.
Aydin Huseynov
analystNice work on the advances this quarter. One thing I'd like to ask about is the bempeg adjuvant melanoma trial. Is there any accelerated approval pathway, maybe a surrogate endpoint such as CR in the metastatic setting, that could support the argument in the adjuvant melanoma case? And on the enrollment side as well. My understanding is that it used to be 1,100 patients. Can you clarify what the target enrollment number is right now?
Jennifer Ruddock
executiveWei, would you walk through the study design and take this question?
Wei Lin
executiveAbsolutely. Regarding the adjuvant trial, that’s a fantastic question. I’d say it’s kind of the ultimate goal. Everyone would want a surrogate marker that permits an earlier readout for an adjuvant study, since such a trial can take a very long time on one hand, and it demands a big patient population along with a massive investment, and many patients are definitely waiting because that’s an area where we can offer a cure to numerous patients. So I think that unlike, let’s say, in the metastatic setting, adjuvant is truly difficult when it comes to having enough data to connect some kind of surrogate to either disease-free survival or relapse-free survival. And in melanoma, the most encouraging marker so far, I believe, is probably some form of circulating tumor DNA clearance. But that hasn’t been solidly proven yet. There isn’t a large body of data, as I mentioned, like the FDA meta-analysis where they’ve tied depth of response to long-term survival. There hasn’t been a large body of data from many patients tested with CTDNA in a completed registration trial and linked to CTDNA clearance, say, with either DFS or RFS; so given that gap, I think the feedback from Health Authorities — and I’ve definitely been to several workshops on this — and I think that’s — the FDA made it clear in one workshop that this is the type of data they’re seeking to truly establish a marker like CTDNA clearance as a possible surrogate for accelerated approval, correct? So that’s kind of the — what hasn’t been the — what’s the missing piece when it comes to registration for the adjuvant setting. Now whether such data will appear between now and when our melanoma adjuvant study finishes, I think that remains to be seen. If data like that were to appear and the FDA felt confident about it, that would certainly let them provide — open up — using, say, for example, CTDNA as a surrogate to permit early approval in a Hodgkin’s diagnostic study, followed by delivery of the DFS or RFS in that setting. I hope that addresses your question.
Aydin Huseynov
analystCertainly. Yeah, of course. And regarding how many participants this trial aims to enroll?
Wei Lin
executiveAbout the enrollment goal. Right. Jennifer, please continue.
Jennifer Ruddock
executiveYeah. I was about to mention this — could you walk us through how 950 and 1,100 differ, given that we settled on 950 for the final protocol?
Wei Lin
executiveYes. Is that what you're asking just the number or...
Aydin Huseynov
analystYeah, I'm just wondering.
Jay Olson
analystNice work on the advancement. I wanted to ask about 358, and could you share your thoughts on Amgen's choice lately to stop work on their IL-2 muting in RA and instead concentrate on GI autoimmune conditions? Does IL-2 have some property that makes it especially useful in the GI tract? And might you think about creating 358 for any GI uses?
Jennifer Ruddock
executiveJZ, could you handle that question?
Jonathan Zalevsky
executiveAbsolutely. Yeah, so for sure — we saw that AMG-592, in the context of clinical trials, they put out word about certain changes to that trial. Keep in mind that trial has truly been running for quite a long stretch, correct? They by no means ever gave results on the 1B cohort, and they shifted into the expansion phase in lupus, and after that let everyone know the RA portion of it was discontinued. I'm not — from where I sit, from a scientific perspective, you wouldn't claim that Tregs don't fit a trial in RA. There's certainly some scientific justification behind that. My guess would simply be that their attention was on other indications; at this point we do have knowledge of certain data from a study being conducted in Europe known as TRANSREG; that's a trial carried out by David Klatzmann, in which he employed low-dose IL-2 where, as you're aware, it's possible to achieve a modest level of Treg induction by means of some form of high-frequency dosing schedule, at most a doubling or tripling of cells relative to baseline; however in that trial, 12 distinct autoimmune disease indications were examined, and it was observed that certain GI indications, like ulcerative colitis and Crohn's disease, show a propensity; and from a scientific standpoint, that's quite logical, Jay, since we understand that Tregs serve a significant function in the GI tract. They in fact assist in regulating some of the mucosal immunology occurring between all the microbes on one side of the gut and all of the immune cells on the other side of the gut, and particularly in regions such as Peyer's patch and other components of immunological structures. So it certainly is logical to concentrate on GI indications. And naturally, Amgen keeps its focus on lupus, correct, which has remained the continuing element of their ongoing clinical trial as well.
Corinne Jenkins
analystThis is Corinne Jenkins, filling in for Paul. I was hoping you might expand a bit on your thinking regarding a registrational study in non-small cell lung cancer, and also what the catalyst path is going to look like after that first data from PROPEL comes later this year or early next?
Jennifer Ruddock
executiveThank you, Corinne. Wei, I'd like you to assist Corinne with that question.
Wei Lin
executiveYes, of course. As I mentioned before, within the expansion cohort of the ongoing PROPEL trial, there are actually 3 substudies. One of them enrolls roughly 20 patients who are PD-L1 positive at 50% and above; a second one has 18 or 20 patients falling into the 1% to 49% category; and the group below 1% contains another 20 patients. In every one of these subgroups, we intend to examine response rate together with depth of response and durability of response. The benchmark figures for pembro across these same subgroups are widely recognized and publicly accessible. That makes benchmarking straightforward, and the trial's design, or its analysis plan, was built to compare results against those figures. It will be on the basis of these comparisons with the historic numbers that we determine whether our combination brings the most value — either among the 50% and above patients, where an already inflamed tumor could be made even more inflamed, pushing pembro mono's activity to a higher level and possibly extending durability further; or among the 1% to 49% patients, where pembro mono appears to give survival benefit on par with platinum double chemotherapy alone yet shows no superiority over the existing chemotherapy. On safety, though, it actually comes out ahead; that's another place where I believe a cytokine-based agent such as bempeg holds really strong potential to contribute a great deal of substantial value by inflaming a tumor that is only low to moderately inflamed. Then, clearly, there remain the patients who are basically effectively PD-L1 negative, below 1%. Those are the ones for whom monotherapy fails, being inferior to the chemotherapy that's available. For them, the current standard of care is usually chemo plus pembrolizumab or chemo plus atezolizumab. That certainly does provide clinical benefit, but it truly carries the extra toxicity that comes with combination chemotherapy; and what I think patients and their physicians want is a regimen free of chemo that can offer benefit similar or superior to what chemo plus a checkpoint can actually achieve; so these are really close to 3 distinct subgroups, and for each one decisions will be made independently. The Phase III trials will truly rest on what activity and durability of our responses, along with the depth of response, we observe in the PROPEL study.
Corinne Jenkins
analystWonderful. And, moving to a different topic, could you explain the process by which you chose the solid tumor indications that you're pursuing with NKTR-255? What is the reasoning behind using an IL-15 agent in head and neck cancer as well as colorectal cancer? Also, do you see any additional indications where IL-15 would be a good fit?
Wei Lin
executiveSure. The choice of those 2 tumor types, I believe, stems from several factors. The way I see it — IL-15 exerts its effects on 2 distinct cell populations, among other targets; when it comes to therapeutic impact, one is the affected T cell population, while the other consists of NK cells. At present, our solid tumor trial is genuinely taking advantage of, or concentrating on and attempting to exploit, the NK activity of our 255 molecule. NK cells play a crucial role in delivering the ADCC activity of monoclonal antibodies, and that mechanism underlies many of the current standards of care in oncology. As we examined the full treatment landscape in solid tumors and the places where monoclonal therapy provides benefit, we sought tumor types and drug combinations that still leave potential room for improvement and could yield a proof of concept, after which we can truly broaden the usefulness of 255 across many other solid tumor types, since numerous other monoclonal antibodies are employed in solid tumors besides cetuximab, which is the backbone we're adding on to in this case. I believe head and neck cancer and colorectal cancer present several advantages as that initial first proof-of-concept, because — when given as monotherapy, cetuximab by itself produced a response rate in the 10% to 15% range. So it does have activity, in the same way that single agent chemotherapy has activity, yet it isn't so active that improvement becomes very difficult; this therefore gives a sort of ideal platform for demonstrating and delivering that proof-of-concept, where substantial room for improvement remains for an agent such as 255 that can markedly expand the NK cell population and truly grow the army that these monoclonal antibodies will depend on when carrying out the cell killing of these monoclonal antibodies. I think we can likely see — have the chance to see the strongest signal and have a robust proof of concept established by choosing cetuximab in head, neck and colorectal cancer; so that covers the sort of clinical and biological reasoning. And the other aspect of this: both of these tumor types are — possess a potential population, correct, and one where the EGFR monoclonal antibody such as cetuximab has truly been broadly used and forms part of a strong standard of care. Essentially every patient who has access to these antibodies always gets — requires cetuximab as part of their standard-of-care treatment. And colorectal cancer patients, provided they're KRAS wild-type, they, without exception, either in first line or second line, receive a EGFR monoclonal antibody. The number of patients and the size of the chance here are pretty big, assuming we can show that proof of concept, and there's a clear pathway for registration ahead; and should we manage to show clinical efficacy across these 2 tumor types, well then I believe we hold that kind of potential proof of concept, with 1 monocle antibody across 2 separate tumor types, which really gives strength to our data; and on top of that, the baseline response rate of only 10% to 15% leaves us substantial room to show just how much improvement we can truly deliver; and that lets us genuinely advance into other tumor types, or monoclonal antibodies that are likewise established standard of care in solid tumors.
Daina Graybosch
analystI've got two questions. One has 2 parts, the other just 1. The 2-part question is about NKTR-358. Lilly seems quite enthusiastic regarding lupus, and in the clinic they have several agents for it, among them their JAK and a BTLA inhibitor. So I'm curious how you believe Lilly views its portfolio — will they advance all of them, or select just one? Then the second part of that: conducting clinical trials in lupus has proven genuinely difficult. Could you explain the reasons behind that, and what in your design will let you sidestep the pitfalls seen previously? Then a small question regarding NKTR-262. With the biomarkers you've observed so far, and those we'll see in the fall, I'm wondering whether you'll be able to tease out the relative concentration of TLR 7 versus TLR 8 agonism?
Jennifer Ruddock
executiveGreat. JZ, would you mind handling the 3 questions?
Jonathan Zalevsky
executiveAlright, yes. Thanks for that question, Daina, so let's kick things off there. You raised some points regarding the lupus portfolio at Lilly. Indeed, there are several agents involved, both small and large molecule, including bari as well as BTLA. Fundamentally, those agents, as you're aware, are aimed at activation immunological mechanisms, correct? So a JAK inhibitor blocks signaling through any JAK stat-mediated pathway, so chiefly in the cytokine driven manner. And BTLA likewise blocks one of the co-stimulatory coadapter types of molecules. So one reason Lilly has so much excitement and places such importance on the 358 program is that it's what we term a resolution therapeutic. Conceptually, then, it goes after a separate way of tackling what's actually driving the disease. Lilly's other pipeline agents, and also things like anifrolumab and similar drugs, work by blocking the activation routes of immune and inflammatory pathways — whether those get set off by something like RNA spilling out of dying cells, or by other forms of ongoing systemic inflammation. The Treg approach, though, is meant to switch on the body's own immune-restoring, or immune-resolving, homeostatic pathway. So for these types of diseases, it really is a distinct arm and a distinct strategy. Another crucial piece of this is that, regardless of whether your perspective is very long-term—which yours is—when you're putting together something like a series of several agents aimed at lupus, you begin to see possibilities for combining them. So imagine one medication that halts activation alongside a second medication that promotes resolution; at that point you're describing an approach to treating these conditions that is genuinely rational and grounded in science. Historically, combining agents that halt activation has proven hard, since their toxicity profiles tend to overlap considerably. Yet once more, that difficulty disappears when a resolution therapeutic is part of the picture. That, I think, is among the approaches that genuinely reflect their long-range ambitions in autoimmune disease, and truly in assembling a pipeline that leads the industry in lupus as well as other indications. Regarding what you asked next — the idea of running lupus trials — I'd say that in the past, we came away with a belief and a sense that development in this area is simply extremely difficult, and a few factors shaped that belief, such as how heterogeneous the patient population tends to be. Then there's the reality that no unambiguous tool existed for assessing the disease. You've got SELENA-SLEDAI, BICLA, and BILAG out there, but newer measures have been showing up lately — anifrolumab is one example — and those are beginning to shed some light on this issue. So that's one of the traps, I'd say. The other trap is that, honestly, we simply haven't come across mechanisms with much strength — ones you could actually quantify against the background of standard-of-care steroids that patients are already receiving. Fine, so we've approached this from a number of directions. To start with, we're including every single endpoint that might conceivably be applied when evaluating the disease. The primary endpoint is built around a reduction in SLEDAI-2k, and the secondary endpoints, which you already know about, take in BICLA-BILAG, SRI-4, plus other scoring systems for low disease activity as well. So these genuinely capture all the varied methods rheumatologists use to evaluate and quantify the disease. We're also working to better define the patient group by focusing sharply on individuals who have the appropriate form of severe disease. Every one of them is stratified to have active disease at minimum. Then, naturally, we're also providing the chance to reduce steroid usage over the course of the trial; and the final point from our side is that a well-documented dysfunction of the IL-2 compartment stands as one of the characteristic features of lupus, especially severe lupus. This shows up not only through diminished cytokine levels but also via a decrease in Treg counts and, importantly, a decrease in Treg functionality as well. As you know, this is frequently offset by an excessive abundance or a rise in the quantity of TH17 cells observed in these patients. So what we're truly targeting, I believe, is the fundamental disease pathology, and we're doing so by directing NKTR-358 at the disease. Thus, we're quite optimistic that this design and this mechanism will give us the chance to observe NKTR-358 activity in the Phase IIb study; and clearly we're thrilled since we think the study is now underway. Now, your following question concerned NKTR-262. For the biomarker effort, our main goal is to look hard for signs that we're hitting both TLR7 and TLR8, and to tell those two apart. And you — that's a sharp question, since resiquimod is the drug we attached to the polymer as our starting point, right? So it acts on both TLR7 and TLR8, which means we can look at gene expression across distinct mRNA networks and zero in on the ones more closely linked to TLR7 versus TLR8. On top of that, as you're aware, certain cell types carry more or less of one receptor than the other — take plasmacytoid dendritic cells, for instance, right? Those are specific to TLR8, only TLR8 — they don't express TLR7 at all. Regarding the biomarker initiative we put in place, that covers every part of the deep biopsy work — it includes looking at cellular makeup within those biopsies, plus the gene networks. What we're really aiming for is to demonstrate that whenever we say we're hitting the target, we're able to name it specifically: TLR7, TLR8, both at once, or just one of the two. Appreciate the question, Daina.
Howard Robin
executiveOkay, thanks to all of you for being here with us today. I also want to express appreciation to our team members for the effort and dedication they've shown through what has been a really challenging period for the business world overall. It makes us proud to see how tirelessly our people have pushed our clinical trials forward, kept operations moving along, and steered through these circumstances with optimism and perseverance. We feel lucky and proud that Nektar has assembled a tremendously valuable pipeline of programs in immuno-oncology and in immunology, targeting major areas where medical needs remain unmet, in solid and liquid tumors, spanning numerous possible treatment indications, as well as across multiple autoimmune and chronic inflammatory disease states. As I mentioned before, we hold a distinctive financial position of strength, with a strong balance sheet showing $1.2 billion in cash and zero debt. That allows us to keep up our crucial efforts toward developing potential new medicines capable of transforming patient care. We're grateful to all of you as shareholders for your backing; we're eager to keep bringing you updates on how we're progressing, and we also wish safety and health for you and your loved ones right now. So thanks again for being with us today. We appreciate it.
Operator
operatorThanks, everybody, for joining us on today's call. That brings the program to an end. You're all free to hang up now. Have a great day, everyone.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.